NGS-based technologies that can identify gene fusion events in a partner-agnostic manner have been shown to enable accurate molecular diagnosis of TFE3-rearranged RCC and may be even more broadly adopted in the diagnostic routine in the future [59]. This evidence concerns the gene TFE3 and renal cell carcinoma.